- Home
- CII vs APMD Comparison
CII vs APMD Comparison
Compare CII & APMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CII | APMD |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 895.5M |
| IPO Year | 2004 | 2026 |
Fundamental Metrics
Financial Performance| Metric | CII | APMD |
|---|---|---|
| Price | $23.69 | $15.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $50.33 |
| AVG Volume (30 Days) | 73.5K | ★ 386.6K |
| Earning Date | 01-01-0001 | 11-20-2026 |
| Dividend Yield | ★ 6.17% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $136.18 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.43 | $13.88 |
| 52 Week High | $26.17 | $35.29 |
Technical Indicators
Market Signals| Indicator | CII | APMD |
|---|---|---|
| Relative Strength Index (RSI) | 50.91 | 38.98 |
| Support Level | $23.28 | N/A |
| Resistance Level | $25.15 | $19.83 |
| Average True Range (ATR) | 0.35 | 1.45 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 82.86 | 31.26 |
Price Performance
Historical ComparisonAbout CII Blackrock Capital and Income Fund Inc.
Blackrock Enhanced Cap&Inc Fund, Inc is a closed-end management investment company. Its investment objective is to provide current income and capital appreciation. The trust seeks to achieve its investment objective by investing in a portfolio of equity securities of U.S. and foreign issuers. It may invest directly in such securities or synthetically through the use of derivatives. It also seeks to achieve its investment objective by employing a writing (selling) call and put options.
About APMD Apnimed Inc. Common Stock
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).